Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AuspiCiOus-dMMR
2023-509380-24-00Phase 2Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of retifanlimab in esophageal adenocarcinoma (EAC), gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Amsterdam University Medical Center. Primary endpoint: Interferon gamma expression and number of infiltrating cytotoxic T-cells. Planned start Nov 2021; status: authorised.
02
Drugs
retifanlimab
03
Conditions
esophageal adenocarcinoma (EAC)gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2023-509380-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509380-24-00.